22nd Oct 2020 17:42
Genedrive PLC - Manchester-based molecular diagnostics firm - Completes assay design for point-of-care solution for Covid-19 testing and is generating promising analytical data in line with market requirements.
Targeting the end of 2020 for completion of product evaluations, with the full release of the final CE Marked system in the first quarter of the 2021 financial year.
Current stock price: 105.25 pence
Year-to-date change: up sharply from 22.50p
By Dayo Laniyan; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Genedrive